merged_china-pharma-drugs.txt
<question_number>1</question_number>
<answer>N/A</answer>
<question_number>2</question_number>
<answer>N/A</answer>
<question_number>3</question_number>
<answer>N/A</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>N/A</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Allow patients to get an original branded drug even if it was not on the approved procurement list.</answer>
<question_number>8</question_number>
<answer>N/A</answer>
<question_number>9</question_number>
<answer>N/A</answer>
<question_number>10</question_number>
<answer>N/A</answer>
<question_number>11</question_number>
<answer>China's National Healthcare Security Administration</answer>
<question_number>12</question_number>
<answer>Xia Zhimin</answer>
<question_number>13</question_number>
<answer>Zheng Minhua, the director of surgery at the prestigious Ruijin Hospital in Shanghai</answer>
<question_number>14</question_number>
<answer>volume-based procurement</answer>
<question_number>15</question_number>
<answer>Former editor at a leading online health platform</answer>
<question_number>16</question_number>
<answer>The policy put in place in 2018</answer>
<question_number>17</question_number>
<answer>Lu Changlin</answer>
<question_number>18</question_number>
<answer>China</answer>
<question_number>19</question_number>
<answer>Private clinics</answer>
<question_number>20</question_number>
<answer>Xia Zhimin</answer>
